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ABSTRACT
Aims To study the effectiveness of intensive counselling by a practice nurse (PN) versus brief advice by a general prac-
titioner (GP), each combinedwith pharmacotherapy, for 6months’ tobacco abstinence (primaryoutcome). Secondaryout-
comes included 12-month abstinence, medication adherence and incremental costs per life-year gained. Design A
multi-site (n = 10), two-group, parallel, pragmatic randomized controlled trial. Setting A network of primary health-
care centres in the Netherlands. Participants A total of 295 adult daily smokers (mean age = 48 years; mean
cigarettes/day = 19). Intervention and comparator Patients were randomized to receive individual counselling by a
practice nurse (PN) (n = 149) or brief advice by a general practitioner (GP) (146). All patients received 12 weeks of
open-label varenicline. Measurements The primary outcome was prolonged biochemically validated abstinence from
weeks 9 to 26 after treatment initiation. Secondary outcomes included abstinence fromweeks 9 to 52, good dosing adher-
ence (> 80% days taken) and incremental costs per life-year gained. Findings Abstinence rates in the PN versus GP
groups were 32.2% (n = 48) versus 39.0% [n = 57; odds ratio (OR) = 0.71; 95% conﬁdence interval (CI) = 0.44–1.16]
from weeks 9 to 26 and 25.5% (n = 38) versus 28.8% (n = 42; OR = 0.84, 95% CI = 0.50–1.43) from weeks 9 to 52,
respectively. Values of the Bayes factor indicated that the PN and GP were equally effective. Good dosing adherence was
signiﬁcantly lower in the PN (45.5%, n= 56/123) than in the GP group (62.0%, n= 75/121; OR = 0.45, 95% CI = 0.26–
0.77), and the incremental costs per life-year gained were –€416.10. Conclusions Among people seeking help to stop
smoking from their general practice, one-off brief advice from a general practitioner appears to be as effective as several
sessions of behavioural support from a practice nurse when smoking cessation medication is provided.
Keywords Brief advice, counselling, practice nurse, pragmatic trial, primary care, smoking cessation, tobacco,
varenicline.
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INTRODUCTION
Tobacco smoking remains a world-wide problem. Primary
health care is in a strategic position to assist in smoking
cessation support, especially in countries where a large
percentage of smokers visit a general practitioner (GP)
annually [1,2]. Guidelines recommend that every smoker
visiting a GP is advised to quit and is offered treatment—
preferably a combination of behavioural support with a
pharmacological aid [3–5]. Effective behavioural treat-
ments include brief advice by the GP [6,7] and the
pharmacological aids varenicline [8], bupropion [9] and
nicotine replacement therapy [10], of which varenicline
seems most effective [11–14].
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Practice nurses (PNs) are available as an additional
work-force in Dutch primary care. They are trained to
educate patients, guide medication use and assist to
improve their life-styles [15]. However, their added value
in smoking cessation treatment has not yet been
corroborated by scientiﬁc evidence [16]. We hypothesized
that PNs are more effective than GPs in helping smokers
quit, as they have more time to support patients during
their quit attempt [17]. Also, Dutch PNs are trained in
giving smoking cessation assistance, so they should have
the necessary knowledge and skills to help patients to quit.
As a combination treatment is advised by clinical
guidelines, it is especially valuable to investigate the PNs’
effectiveness when their support is combined with
evidence-based pharmacotherapy. We also hypothesized
that more intensive support of patients would lead to better
adherence to pharmacotherapy. Medication adherence is
related strongly to abstinence from smoking [18], and if
patients do not receive sufﬁcient support they may be more
inclined to stop medication.
The primary aim was to compare the effectiveness of
individual counselling by a PN versus brief advice by a
GP, both combined with open-label varenicline, on
prolonged abstinence from weeks 9 to 26. Secondary aims
were to compare: (1) point prevalence abstinence rates at
week 9; (2) prolonged abstinence rates from weeks 9 to
52; (3) adherence to varenicline; and (4) short-term cost-
effectiveness at week 52.
METHODS
Design
This study was a multi-site two-group parallel randomized
controlled trial evaluating intensive counselling from a PN
versus usual care from a GP, both combined with open-
label varenicline for smoking cessation. A detailed descrip-
tion of the protocol has been published previously [19].
Ethical approval had been obtained (NL30057.068.09/
METC 09–03-075), and the study had been registered in
the Dutch Trial Register (NTR3067). Recruitment, inclu-
sion and randomization started in October 2011 until
December 2013. Treatment and data collection continued
until July 2014. During most of the inclusion period, there
was no reimbursement for varenicline, while this was free
for patients taking part in the trial.
Recruitment
The trial was conducted in a multi-site (n = 10) primary
health-care centre in the Netherlands, covering approxi-
mately 65000 patients (www.sge.nl). This large network
was used to generate results with high external validity.
Patients were recruited by practice assistants, GPs and
PNs and via a brief and easily written leaﬂet displayed in
the waiting room. Daily smokers who were 18 years or
older, ﬂuent in Dutch, and who had no contraindications
for the use of varenicline were included. ‘Light’ smokers
(i.e. smoking fewer than 10 cigarettes per day) were also
included: a growing subgroup of smokers in which
pharmacotherapy can be effective [2,20]. The GP decided
whether or not a patient was eligible for inclusion into
the trial and thus if varenicline was prescribed to the
individual patient.
Randomization
Eligible smokers were assigned randomly in a 1 : 1 ratio,
stratiﬁed by health-care centre, using a six-block scheme,
by means of a computer-generated random number
sequence. The computer disclosed the allocation once
during a phone call by amember of the research teamwith
the assistants of the health-care centre, who then
contacted the patient to schedule an appointment with
the GP or PN. Family members or close friends were paired
and randomized in one cluster to protect against contami-
nation across study groups. Blinding of patients and
health-care professionals was impossible. The member of
the research team who was involved in the randomization
procedure was not involved in the primary outcome
measurement or data analysis. Data analysists were
blinded to group label and identiﬁcation number.
Sample size
Abstinence rates from weeks 9 to 26 were expected to be
35% in the PN group and 20% in the GP group [19]. The
estimated quit rates derived from the results of previous
varenicline trials when using varenicline only [11,12] and
from one of our own smoking cessation trials that combined
individual counselling with nortriptyline [21]. At least 136
patients needed to be included in each group to detect a
15% difference in abstinence with 80% power.
Treatments
PN group
Patients treated by the PN were offered three face-to-face
and seven telephone sessions (maximum 120 minutes
contact time), starting 1 week prior to the quit attempt
until 1 year after the quit attempt, with most contacts
scheduled during the ﬁrst 13 weeks of the quit attempt.
There were no consultations with the GP for smoking
cessation. PNs had received training in delivering counsel-
ling for their routine clinical work according to Dutch
guidelines prior to the start of the trial. The counselling
protocol was developed through an intensive innovation
process involving GPs, PNs and patients [19]. Counselling
included the following evidence-based behaviour change
2238 Carolien van Rossem et al.
© 2017 Society for the Study of Addiction Addiction, 112, 2237–2247
techniques: planning a target quit date; advice on abrupt
quitting and the ‘not a puff rule’; strengtheningmotivation
and self-efﬁcacy; and enhancing a non-smoker identity
[22]. The pragmatic nature of this trial allowed PNs to
deviate from the content and planning of the protocol
when they believed this would beneﬁt their patient.
GP group
Patients treated by the GP received a minimum of one visit
in which the patient received a prescription for varenicline.
Dutch guidelines recommend stimulating the patient’s
motivation during this consultation and to have at least
four follow-up visits during several months [3]. However,
in daily routine practice only minimal advice is usually
given, no quit date is agreed and no follow-up visits are
scheduled. Patients were free to contact their GP in case
of questions or side-effects.
Varenicline (both groups)
All patients received a prescription of 12 weeks’ open-label
varenicline during an initial visit with the PN or GP. The
usual dosage was recommended, but health-care
professionals were allowed to change the dosage when
they believed this would be more appropriate for their
patient [19]. The starting dose of varenicline was dispensed
in the original packaging, and subsequent medication was
offered in Medication Event Monitoring System (MEMS®)
vials from week 3 until the end of treatment.
Measurements
Primary
The primary outcome measure was prolonged abstinence
from weeks 9 to 26 after treatment initiation. Prolonged
abstinence was deﬁned as self-reported prolonged absti-
nence with a maximum of ﬁve cigarettes after a grace
period of 9 weeks, conﬁrmed biochemically by exhaled
carbon monoxide [CO < 10 parts per million], as deﬁned
in the Russell Standard [23]. The smoking status was mea-
sured and validated biochemically at weeks 9, 26 and 52
after treatment initiation. Randomized patients who with-
drew, were lost to follow-up or failed to provide a CO valida-
tion were classiﬁed as smokers.We also measured the point
prevalence rate at week 9 and the prolonged abstinence
rate from weeks 9 to 52 after treatment initiation.
Secondary
Information from the Electronic Medical System was used
to analyse how many consultations and how much
contact time were spent on smoking cessation during a
6-month period after treatment initiation. Information
was based on independent codings, which indicated how
many minutes the consultation lasted, and on
consultations which were registered as encounters for ‘to-
bacco abuse’. A 6-month observation period was chosen
because datawould have been too contaminated with sub-
sequent quit attempts during longer periods of observation.
Medication adherence was measured with the use of
MEMS® vials. Daily adherence (the number of days on
which any dose of medication was taken, with a maximum
drug holiday of 7 days) and persistence (the duration of
medication intake in days with a maximum drug holiday
of 72 hours) was calculated for each patient. Daily
adherence was then dichotomized into good (> 80% of
the prescribed days) or poor adherence. If patients stopped
pharmacological treatment within 2weeks and did not use
a MEMS® vial, their medication adherence was zero days
for the remaining 10 weeks and was therefore identiﬁed
as collected.
Background characteristics
Questionnaires were sent at baseline and at weeks 9, 12,
26 and 52 (see Fig. 1). Information from each respondent
was collected on: baseline demographic characteristics,
self-reported health, past and current smoking behaviour,
nicotine dependence, treatment preferences (i.e. PN
treatment or GP treatment for smoking cessation),
cigarette withdrawal symptoms, smoking-related
cognitions, mental health, quality of life, life events, satis-
faction with the treatment and possible side effects of
varenicline (week 12 follow-up). Also, adverse events
reported spontaneously by the patients during telephone
or personal follow-up contacts were reported. Members of
the research team were not involved in the treatment of
patients, and in case of side effects, patients were advised
to contact their GP or PN.
Statistical analyses
Statistical analyses were conducted using SPSS and R,with
α = 0.05 (two-sided) and by calculating 95% conﬁdence
intervals (CI). All randomized patients were included in
an intention-to-treat analysis [24]. A multiple logistic
regression model with a categorical variable for health-
care centre and a dummy variable for the treatment group
was used to examine whether the odds of prolonged
abstinence from weeks 9 to 26 differed signiﬁcantly
between the two groups. To examine the results for treat-
ment effect heterogeneity, a random effect corresponding
to the treatment group dummy variable was added to the
model. The corresponding variance component was tested
with a likelihood ratio test.
We repeated this analysis adjusted for several
covariates, chosen a priori, measured at baseline: age,
gender, education, income, nicotine dependence, urge to
smoke, self-efﬁcacy, duration of longest quit attempt, de-
pression, anxiety, share of smokers in the social
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environment and alcohol misuse [we refer to this as the
‘adjusted’ odds ratio (OR)] [25–27].
The same analyses were performed to examine the
difference in abstinence at week 9 and weeks 9 to 52.
In a post-hoc analysis, we calculated Bayes factor to
determine the strength of support for the alternative
hypothesis (patients treated by a PN are more likely to quit
smoking) relative to the null hypothesis (no difference)
[28,29]. This is especially useful when faced with non-
signiﬁcant results, as Bayes factor can then be used to
determine whether there is simply lack of evidence for
the alternative hypothesis or whether the evidence actu-
ally supports the null hypothesis. A Bayes factor higher
than 1 indicates support for the alternative hypothesis,
while a Bayes factor lower than 1 indicates support for
the null hypothesis. Values of Bayes factors higher than 3
or lower than 1/3 are regarded as substantial evidence
for the alternative or the null hypothesis, respectively.
Daily medication adherence and medication persis-
tence were compared across treatment groups. Median
and interquartile ranges were computed because the data
showed an expected non-normal (skewed) distribution.
Good adherence was analysed using a logistic regression
model and was adjusted for the same covariates as the
primary analysis. Missing values may not have been
missing at random or completely at random, because
Figure 1 Study ﬂow-chart. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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patients who were more successful in quitting and/or
had more contact with the PN were probably more
likely to hand in their MEMS® vial. Therefore, besides
a complete case analysis, we also conducted best/
worst-case sensitivity analyses for daily adherence,
where all missing values in the PN group were replaced
by good adherence and all missing values in the GP
group were replaced by poor adherence (best case) and
vice versa (worst case) [30].
Due to the pragmatic design, a full cost-effectiveness
analysis from a societal perspective was not possible.
Instead, we calculated the incremental costs per life-year
gained. The costs refer to PN and GP consultations during
6 months after treatment initiation derived from the
Electronic Medical System and based on independent
codings combined with reference prices for Dutch
economic health-care evaluations (€17 per PN consulta-
tion, €33 per GP consultation) [31]. Cost for varenicline
was based on adherence data and the consumer price
in 2012 (i.e. €50 per 2 weeks). The life-years gained were
estimated based on a method by Stapleton et al. [32]. We
assumed the 3.5% discounted number of life-years gained
that could be attributed to our smoking cessation
intervention to be 1.9956 per patient (for the age group
45–54, i.e. the mean age of our sample). The incremental
cost-effectiveness ratio (ICER) was calculated as (costs PN
group – costs GP group)/(life-years gained PN group –
life-years gained GP group).
RESULTS
From 311 smokers whowere randomized initially, 16 were
found to be ineligible after randomization and were
therefore excluded, resulting in a sample size of 295
(range = 9–52 smokers per study site; Fig. 1). Mean age
was 48 [standard deviation (SD) = 13.2] years, 22.4%
(n = 66) had a low socio-economic status, mean cigarettes
per day was 19 (SD = 8.1) and 18.0% (n = 53) were light
smokers (< 10 cigarettes per day). The PN (n = 149) and
GP (n= 146) groupwere comparable at baseline, although
there seemed to be slightly more men and more patients
with cardiovascular disease in the former group (Table 1).
Individual conﬁrmation of the patients’ smoking status
during follow-up was complete in 91% (n = 269) of
patients at week 26 and 85% (n = 251) at week 52. There
were no differences in attrition rates between both
treatment groups at any time-point.
Abstinence
Prolonged abstinence rates in the PN and GP group were
32.2% (n = 48) and 39.0% (n = 57) from weeks 9 to 26
and 25.5% (n = 38) and 28.8% (n = 42) from weeks 9 to
52, respectively (Table 2, Fig. 2). The ORof abstinence from
smoking from weeks 9 to 26 in the PN group compared
with the GP group was 0.71 (95% CI = 0.44–1.16), and
the adjusted OR was 0.76 (95% CI = 0.45–1.30). There
was no indication of treatment effect heterogeneity in the
Table 1 Baseline characteristics of patients in the practice nurse (PN) and general practitioner (GP) group.
PN group (n = 149) GP group (n = 146)
Age, years 47.3 ± 13.4 48.7 ± 12.9
Men 79 (53.0) 60 (41.1)
Education (scale 1–7 = highest) 3.4 ± 1.6 3.6 ± 1.5
Income (scale 1–6 = highest) 3.1 ± 1.3 3.1 ± 1.3
Socio-economic statusa
Low 36 (24.4) 30 (20.5)
Medium 95 (63.8) 95 (65.1)
High 18 (12.1) 21 (14.4)
Cigarettes per day 19.3 ± 8.2 18.7 ± 8.0
Nicotine dependence (scale 0–6 = highest level)b 3.2 ± 1.3 3.0 ± 1.4
Urge to smoke: how many times (scale 0–5)e 2.7 ± 1.1 2.6 ± 1.2
Urge to smoke: strength of urges (scale 0–5)e 2.8 ± 0.9 2.7 ± 0.9
Self-efﬁcacy (scale 1–5 = highest level) 2.4 ± 0.8 2.5 ± 0.9
Longest duration of previous quit attempt in years 0.7 ± 1.8 1.0 ± 3.3
Depression (scale 0–21 = highest level)c 4.3 ± 3.7 4.0 ± 3.5
Anxiety (scale 0–21 = highest level)c 6.8 ± 3.8 6.5 ± 3.5
Share of smokers in social environment (scale 0–5 = highest)d 2.3 ± 1.1 2.2 ± 1.0
Alcohol use (scale 0–7 = highest frequency) 3.1 ± 1.9 2.9 ± 2.2
Self-reported current or previous cardiovascular disease 28 (18.8) 20 (13.7)
Self-reported current or previous severe psychiatric condition 3 (2.0) 3 (2.1)
Data are presented asmean ± standard deviation (SD) or n (%). aSocio-economic status was based on education and income; bmeasuredwith the Heaviness of
Smoking Index [42]; cmeasured with the Hospital Anxiety and Depression Scale [44]; dcomposite of questions about smokers in social environment: smoking
partner (counted double), smoking family members, smoking friends and smoking co-workers; emeasured with the Strength of Urges To Smoke scale [43].
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unadjusted (χ2 = 0.15, d.f. = 1, P = 0.69) and adjusted
(χ2 = 0.00, d.f. = 1, P= 1.00) models. The ORand adjusted
OR of abstinence from weeks 9 to 52 were 0.84 (95%
CI = 0.50–1.43) and 0.98 (95% CI = 0.56–1.72), respec-
tively. Again, no statistically signiﬁcant evidence of treat-
ment effect heterogeneity was found (χ2 = 1.44, d.f. = 1,
P = 0.23 and χ2 = 1.74, d.f. = 1, P = 0.19 in the
unadjusted and adjust model, respectively). Values of the
Bayes factor were below or close to 1/3 which supports
the null hypothesis, indicating that the PN and GP were
equally effective. We noticed considerable variation in the
6-month abstinence rates across health-care centres,
ranging from0 to 63.2%, although the number of included
patients was somewhat small in some centres and the
corresponding abstinence rates were therefore not reliable
(Table 3).
We repeated our primary analysis with a cut-off point of
8 p.p.m. for exhaled carbon monoxide to validate absti-
nence biochemically [33], which showed exactly the same
result. We also repeated our primary analysis in the sub-
group of light smokers and found abstinence rates from
weeks 9 to 26 of 47.8% (n = 11) in the PN group and
36.7% (n = 11) in the GP group, respectively.
Counselling
The received dose of counselling and the association with
abstinence is shown in Table 4. The median number of
consultations with the PN was 7 [interquartile range
(IQR) = 4–9], and the median time spent was 110 minutes
(IQR = 75–135). In the GP group, the median number of
consultations was 1 (IQR = 1–2), and the median time
spent was 10 minutes (IQR = 10–10). In 41 patients
(two from PN, 39 from the GP group), no consultation
data were registered. Also, 13 patients in the GP group
received counselling from the PN and 13 patients in
the PN group had contact with the GP in the context
of smoking cessation. A sensitivity analysis in which 59
patients with missing data or who were treated by the
wrong health-care provider were excluded did not
change the primary outcome.
Treatment preference and satisfaction
Before study enrolment, 67.5% (n = 199) of the patients
had a preference for intensive counselling with the PN
instead of brief advice from the GP. Additionally, varenicline
was expected the most important form of therapy (67.5%,
Table 2 Biochemically validated point prevalence and prolonged abstinence rates in the practice nurse (PN) and general practitioner (GP)
group with associated odds ratios and Bayes factors.
Weeks
Overall
(n = 295)
PN group
(n = 149)
GP group
(n = 146)
OR (95%CI),
Bayes factor Adjusted OR (95%CI), Bayes factor
9 180 (61.0) 86 (57.7) 94 (64.4) 0.73 (0.45–1.19),0.13a 0.80 (0.47–1.36), 0.16a
9–26 (primary outcome) 105 (35.6) 48 (32.2) 57 (39.0) 0.71 (0.44–1.16), 0.14b 0.76 (0.45–1.30), 0.18b
9–52 80 (27.1) 38 (25.5) 42 (28.8) 0.84 (0.50–1.43), 0.24c 0.98 (0.56–1.72), 0.37c
Data are presented as n (%) or odds ratio (OR) with 95% conﬁdence interval (CI). The ORwas adjusted for health-care centre. The adjusted ORwas in addition
adjusted for age, gender, education, income, nicotine dependence, urge to smoke, self-efﬁcacy, longest duration of previous quit attempt, depression, anxiety,
share of smokers in the social environment and alcohol use. For the computation of the Bayes factors, the effect sizes used to specify the standard deviation for
the half-normal distributions representing the alternative hypotheses (see [29] for details) were based on the following hypotheses: abstinence rates in GP and
PN group are: a52.0 and 29.7% (OR = 2.56) in week 9, b35.0 and 20.0% (OR = 2.15) in weeks 9–26, c26.5 and 15.2% (OR = 2.00) in weeks 9–52, respec-
tively, based on 136 participants in each group according to the sample size calculation [19]. The estimated quit rates for weeks 9–26 derived from the results
of previous varenicline trials when using varenicline only [11,12] and from one of our own smoking cessation trials combining individual counselling with
nortriptyline [21]. The estimations for week 9 and weeks 9–52 were extrapolated from that, based on the average percentage point decrease per time-point.
Figure 2 Carbon monoxide-validated
prolonged abstinence rates from smoking rates
up to 52 weeks after treatment initiation in the
practice nurse (PN) and general practitioner
(GP) group. [Colour ﬁgure can be viewed at
wileyonlinelibrary.com]
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n = 172), compared to intensive counselling by a PN
(22.7%, n = 58) and brief advice by a GP (9.8%, n = 25).
Later, at week 9 after treatment initiation, patients were
more satisﬁed with the counselling from the PN
(mean = 7.91, SD = 2.19) than with the brief advice from
the GP (mean = 6.38, SD = 2.91; P< 0.001). As with the
quit rates, there were relevant differences between the
health-care centres in satisfaction with the received
treatment (Table 3).
Daily medication adherence and medication persistence
All patients collected a starting dose of varenicline. In total,
we collected medication adherence data in 244 patients
(82.7%): 123 and 121 patients in the PN and GP groups,
respectively. In the PN group, 45.5% (n=56) had good ad-
herence compared to 62.0% (n = 75) in the GP group
(OR = 0.45, 95% CI = 0.26–0.77; adjusted OR = 0.37,
95% CI = 0.20–0.67). The best/worst-case sensitivity
analyses yielded ORs of 1.12 (95% CI = 0.70–1.81)
and 0.24 (95% CI = 0.14–0.39), respectively, neither
of which indicated signiﬁcantly higher chances for good
adherence in the PN group (the adjusted ORs led to the
same conclusion) (Table 5). Median daily adherence (nu-
meric variable) was 43 days (IQR = 14–73) for the PN
group and 69 days (IQR = 17.5–71) for the GP group.
Median persistence (time variable) was 38 days
(IQR = 10–73) for the PN group and 68 days (IQR = 17–Ta
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Table 4 Counselling intensity and associated abstinence rates in
the practice nurse (PN) and general practitioner (GP) group.
Patients Non-smokers
PN group (n = 149) n sessions with PN
1–4 39 (26.2) 4 (10.3)
5–8 73 (49.0) 26 (35.6)
>8 37 (24.8) 18 (48.6)
n minutes with PN
15–60 30 (20.1) 4 (13.3)
61–120 67 (45.0) 18 (26.9)
>120 52 (34.9) 26 (50.0)
GP group (n = 146) n sessions with GP
1 117 (80.1) 47 (40.2)
2 20 (13.7) 7 (35.0)
>2 9 (6.2) 3 (33.3)
n minutes with GP
10 114 (78.1) 45 (39.5)
11–20 16 (11.0) 7 (43.8)
>20 16 (11.0) 5 (31.3)
Data are presented as n (%). The presented abstinence rates show prolonged
self-reported validated abstinence rates fromweeks 9 to 26. The number and
time of consultations were extracted from the Electronic Medical Record. No
consultations were registered in 39 patients from the GP group and in two
patients from the PN group. These data were imputed with 30 minutes
and one consultation in the PN, and 10 minutes and one consultation in
the GP, as these ﬁrst consultations were mandatory to receive the medica-
tion prescription.
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71) for the GP group. In both groups a substantial num-
ber of patients took medication for longer than the pre-
scribed period, probably by taking only one pill instead of
two pills per day: 41 patients in the PN group and 40
patients in the GP group.
Reported side effects
In total, ﬁve adverse events were reported, all relating to
psychological disorders. One patient died of cardiovascular
disease during the trial period. However, this patient
belonged to the group which was excluded after
randomization, because the GP did not give permission to
participate (the patient did not receive any varenicline).
An overview of reported side effects in the 12-week
questionnaire can be found in Supporting information,
Appendix 1.
Incremental costs per life-year gained
Only patients for whom medication adherence data were
available were taken into account. Data were available for
123 patients in the PN group and 121 patients in the GP
group. This resulted in relatively higher quit percentages
for the cost analysis at weeks 9–52: 26.0% (n = 32) and
33.1% (n= 40) for the PN group and the GP group, respec-
tively. The ICER was –€416.10, meaning that the PN
group produced fewer life-years gained at higher costs
compared with the GP group (Table 6).
DISCUSSION
Intensive smoking cessation counselling by the PN did not
increase abstinence rates compared with brief advice from
the GP in patients who were treated with open-label
varenicline. Overall rates of prolonged abstinence were
high at 26 weeks (35.6%) and 52 weeks (27.1%) follow-
up. In the GP group, adherence to varenicline was
signiﬁcantly better, and the intervention resulted in more
life-years gained at lower costs. Despite the lack of added
effectiveness, 70% of the patients had a preference for the
PN prior to randomization, and patients treated by the
PN were more satisﬁed with their treatment.
This study revealed high percentages of prolonged
abstinence during follow-up in both treatment groups at
26 weeks (32.2%, 39.0%) and at 52 weeks (25.5%,
28.8%) for the PN and GP, respectively. It is also one of
the ﬁrst studies showing quit rates for vareniclinewith only
very limited behavioural support (as in the GP group) in
the same range as varenicline studies with much more
behavioural support [11,12,34,35]. For example, the study
by Swan et al. also used varenicline in real life, and showed
similar cessation rates when combined with various
intensities of assistance (30.7–33.8% at 26 weeks) [34].
In our power calculations, we underestimated the effective-
ness of the GP in smoking cessation. A success rate of 35%
in the PN group and 20% in the GP group was
hypothesized, based on previously published trials
[11,12]. We expected a lower quit rate for the GP because
of our pragmatic design.
Table 5 Complete case and sensitivity analyses for adherence.
Patients analysed
Good adherence
PN group
Good adherence
GP group OR (95% CI) Adjusted OR (95% CI)
Complete case analysis 244 (82.7) 56 (45.5) 75 (62.0) 0.45 (0.26–0.77) 0.37 (0.20–0.67)
Sensitivity analysis 1 (best case) 295 (100.0) 82 (55.0) 75 (51.4) 1.12 (0.70–1.81) 1.10 (0.67–1.81)
Sensitivity analysis 2 (worst case) 295 (100.0) 56 (37.6) 100 (68.5) 0.24 (0.14–0.39) 0.20 (0.11–0.35)
Data are presented as n (%) or odds ratio (OR) with 95% conﬁdence interval (CI). The ORwas adjusted for health-care centre. The adjusted ORwas in addition
adjusted for age, gender, education, income, nicotine dependence, urge to smoke, self-efﬁcacy, longest duration of previous quit attempt, depression, anxiety,
share of smokers in the social environment and alcohol use. Sensitivity analysis 1 replaced all missings for the general practitioner (GP) groups with ‘poor
adherence’ and all missings for the practice nurse (PN) group with ‘good adherence’. Sensitivity analysis 2 replaced all missings for the GP groups with ‘good
adherence’ and all missings for the PN group with ‘poor adherence’.
Table 6 Incremental costs (€) and life years (LY) gained in the practice nurse (PN) and general practitioner (GP) group.
Total
(n)
Costs of
varenicline
Costs of PN
consultations
Costs of GP
consultations
Total
costs
Abstinence week
9–52 (n, %)
Mean LY
gained/quitter
Total LY
gained ICERa
PN 123 25 600 13 515 264 39 379 32 (26.0) 1.9956 616.65 416.10
GP 121 27 450 204 5082 32 736 40 (33.1) 1.9956 410.10
The total number of patients differs from the randomized patients as only patients for whom adherence datawas available were taken into account. The costs
per LY gained were estimated based on a method by Stapleton et al. [32]. aICER = incremental cost effectiveness ratio = (total costs PN group – total costs GP
group)/(total LY gained PN group – total LY gained GP group).
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Although PNs were trained more intensively in giving
smoking cessation assistance than the GPs in our study
and had much more contact time with the patients, their
behavioural counselling did not seem to improve smoking
cessation rates. In a randomized controlled trial with a
similar design, but from a very different setting (US
criminal justice system), behavioural counselling was also
not more effective than brief physician advice when
combined with pharmacotherapy [36]. Contrary to our
hypothesis, medication adherence in the GP group was
signiﬁcantly better than in the PN group, which might
partly explain the higher quit rate [18,37]. A possible
explanation for the lower adherence in the PN group, as
reported previously [36], might be that pharmacotherapy
is seen as less important when provided with intensive
behavioural counselling than when provided with only
very limited behavioural support. It might also be that
PNs advised patients earlier to stop the use of varenicline
in case of side effects than did the GP.
We found striking differences in effectiveness between
health-care centres. Variance between PNs and GPs can
occur naturally, despite that the health-care professionals
in our study had received the same training regarding
smoking cessation. Also, the different social and cultural
background of neighbourhoods in which the health-care
centres were located could have inﬂuenced the results.
Patients with a low socio-economic background tend to
have more difﬁculties with succeeding in quitting
[38,39]. Selecting a large health-care centre with 10
different locations increased the diversity but also the
generalizability of the results.
Although the GP costs per life-year gained were much
lower than the PN costs, this result should be treated
with some caution. First, the cost-effectiveness analyses
used a straightforward and slightly insensitive measure.
Secondly, the costs could not be calculated for the total
group of patients, as medication adherence data were
incomplete. This resulted in a lower relative increase in
the smoking cessation rate for the PN than for the GP
group (2.0 versus 14.9%), which could have inﬂuenced
the outcome of cost-effectiveness in favour of the GP.
Although it seems likely that treatment by the PN is
more expensive, both treatments can be regarded
extremely cost-effective [40]. Also, as involving GPs in
smoking cessation during routine care is difﬁcult, PNs
could still play a crucial role in access and reach of
smoking cessation in primary care.
Strengths and limitations
The main strength of the current study is its pragmatic
design, which was used speciﬁcally to increase the general-
izability of our ﬁndings. Patients with real-life comorbidities
and life-style factors may respond differently to a
combination treatment of varenicline with GP advice or
PN counselling than selected patients in pre-clinical re-
search settings [41]. A more elaborated overview of the ele-
ments that made this study pragmatic can be found in our
published study protocol [19]. Although smoking is a bigger
problem in patients with a low socio-economic status,
smokers with higher socio-economic status are usually
more likely to participate in research [39]. In our study,
however, patients with low socio-economic status were well
represented, which indicates good generalizability of the re-
sults. Furthermore, this is the ﬁrst study assessing and com-
paring adherence to varenicline in patients treated by GPs
and PNs electronically with MEMS®. Also, we succeeded in
including a large percentage of potentially eligible patients
(76.8% of 384 smokers who contacted the research team).
Nonetheless, some limitations need to be mentioned.
The sample size of our trial was large enough to detect
the hypothesized difference of 15% in 6-month abstinence
rates between the groups, but our statistical power was too
low to detect a difference of 10% or lower, which may also
be regarded as clinically relevant. Blinding to treatment
group was not possible, and some contamination occurred
in both groups. The latter could have been prevented by a
cluster randomized trial design. However, our practice net-
work did not offer enough clusters, and our sensitivity anal-
ysis, excluding patients who crossed over, did not change
our primary outcome. We were also not able to monitor
the quality of the behavioural support or the treatment ﬁdel-
ity in both groups. This makes it difﬁcult to determine why
the intensive consultations by the PN did not lead to more
quitters andwhy therewere large differences in effectiveness
between health-care centres. Nevertheless, we assume that
the PNs in the study are representative for PNs in the
Netherlands as a whole. Furthermore, a small number of
patients who did not collect varenicline from the pharmacy
was excluded. Therefore, results may not be generalizable
to every single patient who would enrol in such a cessation
programme, but only to those motivated enough to collect
medication. As the number of excluded patients was simi-
lar in both groups, however, we do not expect this to have
biased our results.
CONCLUSION
It is generally possible to achieve high smoking cessation
rates in primary care with a treatment programme that
combines behavioural support with pharmacotherapy.
However, intensive smoking cessation counselling by a
PN does not seem to improve abstinence rates compared
with brief GP advice in patients who are treated with
standardized pharmacotherapy. Nonetheless, both treat-
ments seem extremely cost-effective, and as GPs are
difﬁcult to get involved in smoking cessation routinely,
PNs can still play an important role in providing
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accessible smoking cessation treatment in primary care.
The possible mediational effect of adherence should be
investigated further, and also why adherence might be
better in smokers treated by their GP.
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